Work

Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia

Year: 2017

Type: article

Source: Blood

DOI: 10.1182/blood.v130.suppl_1.2899.2899

Authors: May Garrett, Beverly Knight, Jorge E. Cortés, Michael W. Deininger

Institutions: Pfizer (United States), The University of Texas MD Anderson Cancer Center, University of Utah

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3047468976

FWCI: 0.543

Cites:

Cited by: 6

Related to: 1